Dr. Rony Abou-Jawde, MD

Claim this profile

Mosaic Life Care

Studies Colorectal Cancer
Studies Solid Tumors
3 reported clinical trials
7 drugs studied

Area of expertise

1Colorectal Cancer
Rony Abou-Jawde, MD has run 2 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
GNAQ positive
2Solid Tumors
Rony Abou-Jawde, MD has run 2 trials for Solid Tumors. Some of their research focus areas include:
BRAF positive
Stage IV
GNAQ positive

Affiliated Hospitals

Image of trial facility.
Mosaic Life Care
Image of trial facility.
Mosaic Life Care At Saint Joseph - Medical Center

Clinical Trials Rony Abou-Jawde, MD is currently running

Image of trial facility.

IDE196 Combinations

for Solid Tumors

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Recruiting1 award Phase 1 & 29 criteria
Image of trial facility.

FORE8394

for Cancer

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Recruiting1 award Phase 2

More about Rony Abou-Jawde, MD

Clinical Trial Related6 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Rony Abou-Jawde, MD has experience with
  • Binimetinib
  • Crizotinib
  • IDE196
  • Bevacizumab
  • FOLFIRI
  • RGX-202-01

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Rony Abou-Jawde, MD specialize in?
Is Rony Abou-Jawde, MD currently recruiting for clinical trials?
Are there any treatments that Rony Abou-Jawde, MD has studied deeply?
What is the best way to schedule an appointment with Rony Abou-Jawde, MD?
What is the office address of Rony Abou-Jawde, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security